allovir
announces
oral
data
presentations
american
society
hematology
annual
meeting
cambridge
globe
newswire
allovir
nasdaq
alvr
late
cell
therapy
company
announced
present
three
abstracts
oral
presentations
support
pipeline
allogeneic
cell
therapies
american
society
hematology
ash
annual
meeting
exposition
taking
place
virtually
december
details
presentations
ash
follows
presentation
title
using
allogeneic
cells
treat
high
risk
patients
session
name
adoptive
immunotherapy
mechanisms
new
approaches
adoptive
cell
therapy
beyond
car
cells
session
date
time
monday
december
presentation
time
pt
et
presenter
spyridoula
vasileiou
center
cell
gene
therapy
baylor
college
medicine
texas
children
hospital
methodist
hospital
abstract
number
abstract
highlighted
ash
press
briefing
saturday
december
pt
et
presentation
title
treatment
severe
viral
infections
allogeneic
specific
cell
therapy
patients
following
hsct
results
phase
study
session
name
adoptive
immunotherapy
mechanisms
new
approaches
adoptive
cell
therapy
beyond
car
cells
session
date
time
monday
december
presentation
time
pt
et
presenter
ifigeneia
tzannou
center
cell
gene
therapy
baylor
college
medicine
texas
children
hospital
methodist
hospital
abstract
number
presentation
title
economic
clinical
burden
virus
associated
hemorrhagic
cystitis
patients
following
allogeneic
hematopoietic
stem
cell
transplantation
session
name
health
services
conditions
lymphoid
disease
session
date
time
monday
december
presentation
time
pt
et
presenter
joseph
mcguirk
university
kansas
cancer
center
abstract
number
allovir
allovir
leading
late
cell
therapy
company
focus
restoring
natural
immunity
viral
diseases
patients
severely
weakened
immune
systems
company
innovative
proprietary
technology
platforms
leverage
allogeneic
specific
cells
targeting
devastating
viruses
patients
cell
deficiencies
risk
consequences
viral
diseases
allovir
technology
manufacturing
process
enables
potential
treatment
prevention
spectrum
devastating
viruses
single
allogeneic
cell
therapy
company
advancing
multiple
clinical
trials
across
product
portfolio
information
visit
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
statements
regarding
allovir
development
regulatory
status
product
candidates
strategy
business
plans
focus
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
related
allovir
financial
results
timing
completion
allovir
clinical
trials
product
candidates
whether
allovir
product
candidates
receive
approval
food
drug
administration
fda
foreign
regulatory
authorities
competition
biopharmaceutical
companies
risks
identified
allovir
sec
filings
allovir
cautions
place
undue
reliance
statements
speak
date
made
allovir
disclaims
obligation
publicly
update
revise
statements
reflect
change
expectations
events
conditions
circumstances
statements
may
based
may
affect
likelihood
actual
results
differ
set
forth
statements
statements
contained
press
release
represent
allovir
views
date
hereof
relied
upon
representing
views
subsequent
date
media
contact
courtney
heath
scientpr
investor
contact
medha
chadha
allovir
ir
